REG - Byotrol PLC - Exercise of Options & Total Voting Rights

ByotrolAnnouncement

14/10/2020 16:30

RNS Number : 1109C
  
Byotrol PLC
  
14 October 2020
  
 

 
 
Byotrol plc ("Byotrol or the Company") 
 
Exercise of Options and Total Voting Rights 
 
 
 
Byotrol plc, the AIM-quoted anti-microbial technology company, announces that it has allotted a total of 307,125 new ordinary shares of 0.25 pence each in the capital of the Company ("Ordinary Shares") following the exercise of options by certain employees, all of whom are below Board level. 
Application has been made for the 307,125 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 20 October 2020.
After Admission, the total number of Ordinary Shares in issue will be 443,149,405 and the total number of voting rights will therefore be 443,149,405. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
 
 
Enquiries:
 
Byotrol plc             
David Traynor - Chief Executive Officer
Nic Hellyer - Chief Financial Officer                                                                                                01925 742 000
 
finnCap
Geoff Nash/Kate Bannatyne - Corporate Finance                                                                          020 7220 0500
Richard Chambers - ECM
 
Flagstaff Strategic and Investor Communications
Tim Thompson/Andrea Seymour/Fergus Mellon                                                                           020 7129 1474
byotrol@flagstaffcomms.com
 
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.
Notes to Editors:
Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.
Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.
Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone. 
For more information, please go to byotrol.co.uk
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
IOEFFDFILESSESS